| Oct 18 |
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
|
| Oct 12 |
Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments
|
| Oct 9 |
Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT)
|
| Oct 4 |
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Oct 3 |
Exploring High Growth Tech Stocks In The US October 2024
|
| Sep 25 |
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
|
| Sep 24 |
Arcutis' supplemental application for Zoryve accepted by FDA
|
| Sep 24 |
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
|
| Sep 19 |
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
|
| Sep 6 |
Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)
|
